Nuvectis Pharma, Inc. NVCT
Nuvectis Pharma, Inc. (Nasdaq: NVCT) is a hematology drug developer. Its lead program, NXP100 (ciprocopan / HSK39297), is in Phase 3 for paroxysmal nocturnal hemoglobinuria; IgA nephropathy; lupus nephritis. Its next catalyst on record is NXP900: Start of combination study with ALK inhibitor lorlatonib (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NXP900 — Start of combination study with ALK inhibitor lorlatonib (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NXP100 (ciprocopan), oral Factor B inhibitor | PNH (approved in China by NMPA for complement-inhibitor-naive patients); IgAN Phase 3 and lupus nephritis Phase 2 ongoing in China | small molecule | Phase 3 |
| NXP200 (HSK42360), BRAF inhibitor | solid tumors, glioma | small molecule | Phase 1 |
| NXP900, SRC/YES1 kinase inhibitor | advanced solid tumors (Phase 1b single agent and with osimertinib ongoing) | small molecule | Phase 1 |
| NXP800 | ovarian cancer (further development in ovarian not pursued) | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 hematology companies
- Incyte Corp INCY
- Grifols SA GRFS
- Disc Medicine, Inc. IRON
- Agios Pharmaceuticals, Inc. AGIO
- Geron Corporation GERN
- X4 Pharmaceuticals, Inc XFOR
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.